Supporting Information

Proteomics Guided Discovery of Flavopeptins: Anti-Proliferative Aldehydes Synthesized by a Reductase Domain-Containing Nonribosomal Peptide Synthetase

Yunqiu Chen[‡], Ryan A. McClure[‡], Yupeng Zheng, Regan J. Thomson^{*}, Neil L. Kelleher^{*}

Department of Chemistry, Northwestern University, 2145 Sheridan Road, Evanston, IL, 60208, USA

Corresponding Author

* n-kelleher@northwestern.edu

* r-thomson@northwestern.edu

‡These authors contributed equally.




Figure S1. Phylogenetic tree built using 159 NRPS condensation domains and the six condensation domains from the flavopeptin biosynthetic gene cluster (shown in red). The 159 condensation domains with known subtypes (LCL, DCL, dual and starter) were extracted from reference 20 (Rausch, C.; Hoof, I.; Weber, T.; Wohlleben, W.; Huson, D. H. *BMC Evol. Biol.* **2007**, *7*, 78.). Sequence alignment was done by MUSCLE and the phylogeny was reconstructed using phyml, employing the JTT model of amino acid substitution. FlavA C1 falls into the category of starter C domain, FlavB C1 belongs to DCL subtype, and other C domains are all LCL types.

FlavB	RPLLTGASGFLGAFLL-RDLVETTGEPVDCLVRAESQQHAAHRVRANLER	
MxcG	QVLLTGATCFVGAHLL-DQLLRQTQAKVVCLVRARDEAHAMERLREAMTS	1142
SfmC	RVFLTGATCYLGLHLV-EQLLRRTDAEVVTLCRARDEQHALERLKEGFAL	1150
NcpB	-ILLTGATCFICAFLL-AELLQQTQADIYCLVRAANLSAGKQRLQETLKA	4486
lgrD	LLTGATGFLGAFLL-RDLLQMTDADIYCLVRASDEEEGMARLRQTLEL	4765
KorD	NIMITGGTGFLGAHLLNKLLMEMEDVKIYCLVRFPSRNRLKDTLMK	661
Tps	IVFLTGATGFLCQEILRQLICNNAIASIITLVRAKSPDHGLDRIRETAKI	20601
AusA	KTLLTGATGFLGAYLIEALQGYSHRIYCFIRADNEEIAWYKLMTNLND	
FlavB	YGLWRPRYADLVHAVPGDLAAPGLGLSAEDRDALVRRLGTVVHNGA	2228
MxcG	QRLSTASLSERVLALPADLGQPWLGLSSARFHGLAAECDMILHNAA	1188
SfmC	YEIDVEDOLHRISAVIGDLAEPRLGLTOEOWDDLAATVDVIYHNGA	1196
NcpB	YLLWEESFNSRIIPVLGDLFOPLLGLGDEOFHFMARKIDLIYHNGA	4532
lgrD	YELWNEEQAHRIIPVIGDLAKPRLNLSEDQFSELAEKVDVLYHNGA	4811
KorD	YGLWQDDFVSRIVVIESDLSKHQFGLDDMTYEKLSNDVSQVYHVGA	707
Tps	AGWWQENYTSKIEIWCGDLSKKRMGLSDVQWARLAGQSSNNVDAIVHNGA	20651
AusA	YFSEETVEMMLSNIEVIVGDFECMDDVVLPENMDTIIHAGA	2140
FlavB	HVNFAAGYRDLRAPNVAGTEELLRLLADSGSPGLHHISTTSVYAPASGPD	2278
MxcG	VVSVVREYGSLQATNVRGTRELLELAASVRPKPLHYVSTLAV-APQANLS	
SfmC	LVNFVYPYSALKAANVGGTORVLELACTTRLKAVHHVSTIDT-LLATHMP	
NcpB	LVNHVYPYALLKAANVGGTEEVLRLASOIKIKPVHFISTVSVFASDEYFK	
lgrD	LVNFVYPYAALKKANVLGTEEILRLAVAKKTKPVHFVSTIFTFASEETEE	4861
KorD	ETNFFEPYSKSKISNVDGVVEMIKFASSYTRKNIYASTLSVLTGERKWD	757
Tps	IVNWNADYDKMRAANVDSTVDLLKATVNSAASPKF1FVSGGIKSDPTTDR	
AusA	RTDHFGDDDEFEKVNVQ-TVDVIRLAQQHHAR-LIYVSTISVGTYFDIDT	
AUSA		2109
FlavB	PVTITESTPPGPPSALPDGYAQSKWVAEQLVGLARERGLPVTVHEP	2324
MxcG	DEVDEA EVDAUD CI DD CVO SEWA A EDI VEOA S EDGI DVEVVEI	1281
SfmC	PEVPEAFVPAHPGLRDGYQQSKWAAFRLVEQASERGLPVT <mark>VY</mark> RL RPFLENDAPLHSAVG <mark>V</mark> PAGYTGSKWVAFKVVDEARRRGIPVTVFRP	1291
NcpB	LDVVQENDPLEHSQGLLGGYTOSKWVAEKIVMMARDRGLPCSIYFL	4628
lgrD		4907
KorD	SMAFREEDMPENSRVLTSCYTOSKWVAEHLVNLARERCIPAAIYPC EEDELVYSPDLMICYSOSKWVAEKLLLQAREHCLTIDIFFL	798
	TILAQYLGNITGYTOTKFVSEGIIQEIINTLPADQNRISTLYP	20744
Tps AusA	EDVTFSEADVYKGQLLTSPYTRSKFYSELKVLEAVKNGLDGRIVFV	2235
AUSA		2235
FlavB	GRISGDTTTGACQERDLLWQLIKGCLQAGAV-DLPHGSTDWVPVDY	2270
MxcG	GRVSGALDSGIVNPQDLVWRILLAGIPAGAL-PQLDVG-EVWTPVDY	
SfmC	GLILGHTKNGATOTIDYLLVALRGFLPMRIL-DYPRI-FDVIPVDY	
NcpB	GRITWHSQTGAWNSNDMFYRFIKSCIQLKSA-PEMNST-VEITVDY	
lgrD	GRMTGDSETGACQKDDLMWRIAAGIIDLGKA-DMSGD-LDMMPVDF	
KorD	GRISSNS-NOVWNEKOMLYKVFESFIEQRIL-FKEEIHFELMPVDF	843
Tps	GRIIGSPETEVANVDDMLWRVVSTAASLRVY-PAEPEE-HWVSVADV	
AusA	ENLTSPYNGRWHMRNIKTNRFSMVMNDLLQLDCIGVSLAEMPVDFSFVDT	2285
F 1 D		0401
FlavB	VSAAVVALATS-GRTDAEVHHYTHPEAPGLDRVFEVAARLGHELRTVPAP	-
MxcG	VARALVRLSLV-PRPGTVFNLTPAPEVR-LSEVFGWVQDYGYPVALCPVP	
SfmC	VASAIVHISRK-REAIDGFYHLFNPAPVPLLTFCDWIKSYGYEFDIVPFE	
NcpB	LTKALIHLSQQ-PESLGKAFHLINSDSAPWSQFINCIRSLGYPLQQLPYE	
lgrD	ASKGIVHLSMT-EQSLSENFHLLNPNSTDYEDLISAIEDRGFVLERVTMD	and the second second second
KorD	VSEF <mark>IY</mark> KISRLNADQKLGIYHMFNDQRVSSEFVTSFFEKNEIPYSNMDLE	
Tps	TTVASSVLSQLYAKEGIAPFVSVAGGMPATIFWDIINKELDVPCEPLSPD	
AusA	TARQ <mark>IV</mark> ALAQVNTPQIIYHVLSPNKMPVKSLLECVKCKEIELVSDESF	NE 2335

Figure S2. Sequence alignment of the reductase domain from FlavB with other NRPS terminal reductases: mxcG (*Stigmatella aurantiaca* Sg a15), sfmC (*Streptomyces Lavendulae*), ncpB (*Nostoc sp.* ATCC 53789), IgrD (*Brevibacillus brevis NBRC 100599*), KorD (*Bacillus sp.* NK2003), TPS (*Hypocrea virens*) and AusA (*Staphylococcus aureus* subsp. aureus str. JKD6008). Conserved residues are colored as follows: hydrophobic in yellow, negatively charged in red, positively charged in violet, serine and threonine in

turquoise, proline and glycine in green, cysteine in pink and asparagine/glutamine in teal. Active site residues are indicated by a star '*'. Residues that interact with NAD(P)H are enclosed in black boxes. The accession numbers for the synthetases indicated are: myxochelin (AAG31130), saframycin (ABI22133), nostocyclopeptide (AAO23334), gramicidin (226312537), koranimine (AEC14349), peptaibol (AAM78457) and aureusimine (384860829).

a MS2 of *m/z* 829.5




Figure S3. MS^2 fragmentation spectra for different flavopeptin species with *m/z* 829.5, 843.5, 871.5 and 885.5, respectively.




Figure S4. Tandem MS for the localization of the first isoleucine residue. (a) Tandem MS reaction mechanism for flavopeptin. (b) The actual spectrum at each stage of MS event. MS^4 spectrum on m/z 240.2 agrees with the predicted fragmentation pattern for the fatty acyl-isoleucine substructure.




Figure S5. Tandem MS showing isoleucine can be incorporated into amino acid positions 1, 3 and 5. (a) Chemical structure and the fragment ion masses for ${}^{13}C_6$ -isoleucine labeled flavopeptin (with *m/z* 863.5) at all possible sites. (b) MS² and MS³ fragmentation of *m/z* 863.5 confirmed that isoleucine can be incorporated into amino acid position 1, 3 and 5.




Figure S6 Determination of the stereochemistry of amino acid building blocks of flavopeptins by Marfey's method. Flavopeptins were hydrolyzed in 6 N HCl at 110°C for 24 h before derivatization by the Marfey's reagent fluorodinitrophenyl-5-L-alanine amide (FDAA) followed by reverse-phase LC-MS analysis. (A) Selected ion chromatograms (SICs) for the FDAA derivatives of amino acids from hydrolyzed flavopeptins. Note that glutamine was converted to glutamic acid during strong acid hydrolysis. The stereochemistry of each amino acid was determined by comparing the retention time with the corresponding standard amino acid derivatives shown in panel (B). The mass tolerance for all SICs was set to be 10 ppm.




Figure S7. Synthetic flavopeptins. (a) LC–MS comparison between the synthetic *N*-octanoyl flavopeptin (**1**, top) and natural flavopeptins isolated from F-6652 (bottom). Shown are the selected ion chromatograms of *m/z* 857.5, with the mass spectra shown as an insert and the MS^2 fragmentation on right. (c) Mass spectrum for the *N*-free amine flavopeptin analog (**3**) showing a dominant peak at 731.4, with very minor (< 10%) dehydrated form.




Figure S8. Dehydrated form of flavopeptins. (a) Mass spectrum of flavopeptins after organic solvent extraction and drying, showing the dehydrated products at m/z 839.5 and 853.5. (b) Proposed structure for the dehydrated form at m/z 839.5. (c) MS² spectrum of m/z 839.5, with the structures of the major fragment masses shown.




Figure S9 Compare the flavopeptin biosynthetic gene cluster among *Streptomyces flavogriseus* ATCC 33331 (top), *Kitasatospora setae* KM-6054 (middle) and *Streptomyces* sp. *Sirex*AA-E (bottom). The three genes (*mbtH*, *flavA and flavB*) in shadow show high sequence similarity among the three strains while other neighboring genes are not highly conserved. Color coding for the genes: red for NRPS, dark blue for MbtH, orange for transcriptional regulators, purple for transporters, green for genes with other annotated functions, grey for hypothetical proteins. The descriptions of genes are shown in the table below.

Streptomyces flavogriseus ATCC		Kitasatospora setae KM-6054		Streptomyces sp. SirexAA-E	
	33331				
Sfla_1343	von Willebrand factor A	KSE_75510	hypothetical protein	SACTE_5051	LysR family transcriptional
					regulator
Sfla_1342	ATPase AAA	KSE_75500	hypothetical protein	SACTE_5053	NmrA family protein
Sfla_1341	hypothetical protein	KSE_75490	putative drug resistance	SACTE_5054	HxIR transcriptional regulator
			protein		
Sfla_1340	hypothetical protein	KSE_75480	hypothetical protein	SACTE_5056	extracellular ligand-binding
					receptor
Sfla_1339	transcriptional regulator	KSE_75470	putative major facilitator	SACTE_5057	hypothetical protein
			superfamily transporter		
Sfla_1338	hypothetical protein	KSE_75460	putative MarR family	SACTE_5058	hypothetical protein
			transcriptional regulator		
Sfla_1337	hypothetical protein	KSE_75450	hypothetical protein	SACTE_5059	hypothetical protein
Sfla_1336	MbtH	KSE_75440	MbtH (74/81%)	SACTE_5060	MbtH (79/90%)
Sfla_1335	NRPS	KSE_75430	NRPS (69/75%)	SACTE_5061	NRPS (80/85%)
Sfla_1334	NRPS	KSE_75420	NRPS (69/75%)	SACTE_5062	NRPS (80/85%)
Sfla_1333	N-acetyltransferase GCN5	KSE_75410	putative polyprenyl	SACTE_5063	hypothetical protein
			diphosphate synthase		

hypothetical protein	KSE_75400	hypothetical protein	SACTE_5064	AsnC transcriptional regulator
hypothetical protein	KSE_75390	hypothetical protein	SACTE_5065	polysaccharide deacetylase
acetyl xylan esterase	KSE_75380	methyltransferase	SACTE_5066	general substrate transporter
IcIR family transcriptional	KSE_75370	hypothetical protein	SACTE_5067	short-chain dehydrogenase
regulator				
fumarate reductase	KSE_75365	hypothetical protein	SACTE_5068	2-dehydropantoate 2-reductase
binding-protein-dependent	KSE_75360	major facilitator superfamily	SACTE_5069	short-chain dehydrogenase
transport system inner		transporter		
membrane protein				
binding-protein-dependent	KSE_75350	hypothetical protein	SACTE_5070	TetR family transcriptional regulator
transport system inner				
membrane protein				
ABC transporter	KSE_75330	hypothetical protein	SACTE_5071	aldo/keto reductase
	hypothetical protein acetyl xylan esterase IcIR family transcriptional regulator fumarate reductase binding-protein-dependent transport system inner membrane protein binding-protein-dependent transport system inner membrane protein	hypothetical proteinKSE_75390acetyl xylan esteraseKSE_75380IclR family transcriptional regulatorKSE_75370fumarate reductaseKSE_75365binding-protein-dependent transport system inner membrane proteinKSE_75360binding-protein-dependent transport system inner membrane proteinKSE_75350binding-protein-dependent transport system inner membrane proteinKSE_75350	hypothetical proteinKSE_75390hypothetical proteinacetyl xylan esteraseKSE_75380methyltransferaseIcIR family transcriptional regulatorKSE_75370hypothetical proteinfumarate reductaseKSE_75365hypothetical proteinbinding-protein-dependent membrane proteinKSE_75360major facilitator superfamily transporterbinding-protein-dependent membrane proteinKSE_75350hypothetical proteinbinding-protein-dependent membrane proteinKSE_75350hypothetical proteinbinding-protein-dependent membrane proteinKSE_75350hypothetical protein	hypothetical proteinKSE_75390hypothetical proteinSACTE_5065acetyl xylan esteraseKSE_75380methyltransferaseSACTE_5066IcIR family transcriptional regulatorKSE_75370hypothetical proteinSACTE_5067fumarate reductaseKSE_75365hypothetical proteinSACTE_5068binding-protein-dependent membrane proteinKSE_75360major facilitator superfamily transporterSACTE_5069binding-protein-dependent membrane proteinKSE_75350hypothetical proteinSACTE_5069binding-protein-dependent membrane proteinKSE_75350hypothetical proteinSACTE_5070




Figure S10. Other peptide aldehyde natural products that inhibit cysteine proteases and the proteasome.




Figure S11. Bioactivities of flavopeptins. (a) Top: Flavopeptins specifically inhibited cysteine proteases such as papain and calpain, while proteases of other types, such as serine (trypsin, chymotrypsin, elastase, subtilisin), aspartic (pepsin), and metallo-protease (thermolysin) were less inhibited. Bottom: The IC_{50} plots against papain using the three synthetic flavopeptins (**1**, octanoyl-I-Q-I-Q-V-F-CHO, **2**, heptanoyl-I-Q-I-Q-I-F-CHO and **3**, NH₂-I-Q-I-Q-V-F-CHO). (b) Flavopeptins showed micromolar range inhibition against the chymotrypsin and caspase-like activities of the human 20S proteasome. Top, the IC_{50} plot for Compound **1**. Bottom, the flavopeptin acid derivative (**4**) did not inhibit the chymotrypsin-like activity of proteasome up to 100 µM. All data points were in triplicates.




Figure S12. ¹H NMR spectrum for **2** in d_6 -DMSO.




Figure S13. ¹³C NMR spectrum for **2** in d_6 -DMSO.




Figure S14. Two-dimensional homonuclear (¹H) TOCSY spectrum for **2** in d_{6} -DMSO. Top: full TOCSY spectrum with amide and α proton regions highlighted. Bottom: side chain signals and associated spin systems are highlighted.




Figure S15. Heteronuclear (¹H-¹³C) NMR spectra for **2** in d_{6} -DMSO with assignments. Top: HSQC spectrum. Bottom: HMBC spectrum.




Figure S16. ¹H NMR spectrum for **1** in d_6 -DMSO.




Figure S17. ¹³C NMR spectrum for **1** in d_6 -DMSO.




Figure S18. ¹H NMR spectrum for **3** in d_6 -DMSO.




Figure S19. ¹³C NMR spectrum for **3** in d_6 -DMSO.




Figure S20. ¹H NMR spectrum for **4** in d_6 -DMSO.




Figure S21. ¹³C NMR spectrum for **4** in d_6 -DMSO.